Adjunctive therapy for severe malaria: a review and critical appraisal
Open Access
- 24 January 2018
- journal article
- review article
- Published by Springer Nature in Malaria Journal
- Vol. 17 (1) , 1-18
Abstract
Despite recent efforts and successes in reducing the malaria burden globally, this infection still accounts for an estimated 212 million clinical cases, 2 million severe malaria cases, and approximately 429,000 deaths annually. Even with the routine use of effective anti-malarial drugs, the case fatality rate for severe malaria remains unacceptably high, with cerebral malaria being one of the most life-threatening complications. Up to one-third of cerebral malaria survivors are left with long-term cognitive and neurological deficits. From a population point of view, the decrease of malaria transmission may jeopardize the development of naturally acquired immunity against the infection, leading to fewer total cases, but potentially an increase in severe cases. The pathophysiology of severe and cerebral malaria is not completely understood, but both parasite and host determinants contribute to its onset and outcomes. Adjunctive therapy, based on modulating the host response to infection, could help to improve the outcomes achieved with specific anti-malarial therapy. In the last decades, several interventions targeting different pathways have been tested. However, none of these strategies have demonstrated clear beneficial effects, and some have shown deleterious outcomes. This review aims to summarize evidence from clinical trials testing different adjunctive therapy for severe and cerebral malaria in humans. It also highlights some preclinical studies which have evaluated novel strategies and other candidate therapeutics that may be evaluated in future clinical trials.Keywords
This publication has 147 references indexed in Scilit:
- Pharmacologic Inhibition of CXCL10 in Combination with Anti-malarial Therapy Eliminates Mortality Associated with Murine Model of Cerebral MalariaPLOS ONE, 2013
- Cerebral MalariaThe American Journal of Pathology, 2012
- CNS Hypoxia Is More Pronounced in Murine Cerebral than Noncerebral Malaria and Is Reversed by ErythropoietinThe American Journal of Pathology, 2011
- Mortality after Fluid Bolus in African Children with Severe InfectionNew England Journal of Medicine, 2011
- Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trialThe Lancet, 2010
- The murine cerebral malaria phenomenonTrends in Parasitology, 2010
- Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapiesNature Reviews Cancer, 2009
- PPARγ agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanismsBrain Research, 2008
- Recovery of Endothelial Function in Severe Falciparum Malaria: Relationship with Improvement in Plasmal‐Arginine and Blood Lactate ConcentrationsThe Journal of Infectious Diseases, 2008
- Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malariaProceedings of the National Academy of Sciences, 2008